INT215204

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.09
First Reported 2007
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 15
Disease Relevance 0.36
Pain Relevance 0.40

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
blood 1
Tg(GH)3Mi (Mus musculus)
Pain Link Frequency Relevance Heat
Bioavailability 30 99.52 Very High Very High Very High
anesthesia 15 70.76 Quite High
Disease Link Frequency Relevance Heat
Body Weight 45 81.52 Quite High
Decapitation 30 72.48 Quite High
Diabetes Mellitus 15 5.00 Very Low Very Low Very Low
Congenital Anomalies 15 5.00 Very Low Very Low Very Low
Endocrine Disease 15 5.00 Very Low Very Low Very Low
Obesity 15 5.00 Very Low Very Low Very Low
Disease 15 5.00 Very Low Very Low Very Low
Infertility 15 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Generally the hGH dose applied in this study (40 ?
Gene_expression (dose) of hGH
1) Confidence 0.09 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0
36 h) increase in IGF-1 and IGFBP-3 that leveled out to correlate to average hGH levels.
Gene_expression (levels) of hGH
2) Confidence 0.09 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0
Serum concentrations of IGFBP-3 are fairly constant throughout the day and are controlled by hGH and IGF-1 levels (43).
Gene_expression (levels) of hGH
3) Confidence 0.09 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0
From these data, following first order reaction kinetics, the rate of hGH absorption (mg hGH/unit of time) into the blood was calculated, using the absorption rate constant in humans derived from absorption half life in humans (t1/2,a?
Gene_expression (absorption) of hGH in blood
4) Confidence 0.09 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0.07
1Where, A1 is the amount of hGH present subcutaneously, R(t) is the amount of hGH released from the microspheres per unit of time, ka is the absorption rate constant, B is the bioavailability of hGH.
Gene_expression (present) of hGH associated with bioavailability
5) Confidence 0.09 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0.10
Fig. 7Binding of 125I-hGH to hGH-antibodies present in sera of Snell dwarf mice having received a single injection microspheres of ATM1 (closed squares) and microspheres of ATM2 (closed triangles) and daily injection of saline (open squares) or daily injection of a solution containing 8.3 ?
Gene_expression (antibodies) of hGH
6) Confidence 0.09 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0
In this figure the binding of radioactively labeled hGH (125I-hGH) to formed hGH antibodies present in the pooled sera of mice is shown.
Gene_expression (antibodies) of hGH
7) Confidence 0.09 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0
g hGH) suspension in saline; group 4 received only at the start of the experiment 0.1 ml of a hGH loaded dex-HEMA microsphere (ATM2; releasing 156 ?
Gene_expression (suspension) of hGH
8) Confidence 0.09 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0.13 Pain Relevance 0.07
0.7 h) obtained by Jorgenson et al. for subcutaneous administration of hGH (35) and a bioavailability of 75% (36) using:
Gene_expression (administration) of hGH associated with bioavailability
9) Confidence 0.09 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0.09
g); group 3 received only at the start of the experiment 0.1 ml of a hGH loaded dex-HEMA microsphere (ATM1; releasing 232 ?
Gene_expression (dex) of hGH
10) Confidence 0.09 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0.07 Pain Relevance 0.07
Since this is not a rapid process, the serum levels of IGF-1 do not follow the pulse in hGH serum levels, but instead the serum levels were paralleled by a delayed (?
Gene_expression (levels) of hGH
11) Confidence 0.09 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0
For the preparation of the CTM batch, no homogenization was used, which resulted in the formation of hGH loaded dex-HEMA microspheres with a [d(0.5)=18.0 ?
Gene_expression (dex) of hGH
12) Confidence 0.09 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0
To investigate the biological activity of released hGH serum levels of IGF-1 and IGFBP-3, two biomarkers for hGH, were also monitored.


Gene_expression (levels) of hGH
13) Confidence 0.08 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0.08 Pain Relevance 0
Fig. 7Binding of 125I-hGH to hGH-antibodies present in sera of Snell dwarf mice having received a single injection microspheres of ATM1 (closed squares) and microspheres of ATM2 (closed triangles) and daily injection of saline (open squares) or daily injection of a solution containing 8.3 ?
Gene_expression (antibodies) of hGH
14) Confidence 0.08 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0 Pain Relevance 0
In this study, we designed an hGH-loaded dex-HEMA microsphere formulation which releases the protein for 7 days.
Gene_expression (dex) of hGH-loaded
15) Confidence 0.08 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0.08 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox